Majority of first-wave COVID-19 clinical trials have significant design shortcomings, study finds

(Johns Hopkins University Bloomberg School of Public Health) Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.